Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor NK cells
- Development stage
- Unknown
- Lead developer
- Peking University First Hospital
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor NK cells (Peking University First Hospital) is an adoptive cell therapy consisting of non-genetically modified natural killer (NK) cells derived from healthy donors. This investigational therapy is being developed by Peking University First Hospital for the treatment of acute myeloid leukemia (AML) relapse in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). The treatment regimen involves the intravenous infusion of donor NK cells in combination with low-dose interleukin-2 (IL-2). The co-administration of IL-2 is intended to support the survival, proliferation, and activation of the infused NK cells, which exert anti-leukemic effects by directly identifying and lysing AML blasts through the release of cytotoxic granules containing perforin and granzymes.
- Other names
- donor NK cells injectionnon-genetically modified natural killer cellsNK cell
Beyond the preview
Go deeper on donor NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor NK cells.